To include your compound in the COVID-19 Resource Center, submit it here.

Aranesp darbepoetin alfa regulatory update

FDA modified the black box warning and recommended more conservative dosing for erythropoiesis-stimulating agents (ESAs) used to treat anemia in chronic kidney disease (CKD) patients. The labels now warn that CKD patients in controlled

Read the full 349 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE